Fasenra (benralizumab) has been granted approval in the European Union as an add-on treatment for adults with relapsing or treatment-resistant eosinophilic granulomatosis with polyangiitis, or EGPA, a rare type of ANCA-associated vasculitis (AAV). The clearance of Fasenra, “with its convenient, single-monthly injection is a positive step forward…
Combination maintenance therapy with Nucala (mepolizumab) and azathioprine may be more effective than either treatment alone at maintaining disease remission and reducing the need for glucocorticoids in people with severe eosinophilic granulomatosis with polyangiitis (EGPA). These are the findings of a single-center study in Japan that support the use…
Alivexis’ experimental oral therapy MOD06051, designed to suppress an underlying mechanism of ANCA-associated vasculitis (AAV), eased blood vessel inflammation and tissue damage in a rat model of the disease, a study from Japan found. In lab-grown human and rat cells, the therapy was shown to block the activity…
Low blood levels of the copper-carrying protein ceruloplasmin at diagnosis are associated with worse survival in adults with ANCA-associated vasculitis (AAV) who test positive for self-reactive antibodies against the myeloperoxidase (MPO) enzyme, a new study from France has shown. “This is the first study associating low [blood] ceruloplasmin level…
ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked by overactivity of the immune complement system, was well tolerated in a Phase 1 clinical trial involving healthy volunteers. The study’s data also indicated that ADX-097 showed a favorable pharmacological…
The long-term use of Nucala (mepolizumab) reduces disease activity and the need for standard glucocorticoids, while improving survival, in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV). These are the findings of a real-world study in Japan that compared outcomes between 37…
The Vasculitis Foundation has announced the launch of a new support group for young adults with vasculitis, a group of autoimmune conditions that includes ANCA-associated vasculitis (AAV). The group will promote connections among young adults, from 18 to 30 years of age, living with vasculitis, which is marked by…
People with ANCA-associated vasculitis (AAV) have a higher risk of cardiovascular diseases and related mortality than people without the disease, according to a systematic review and meta-analysis of published studies. For example, the risk of venous thromboembolism, a blood clot that develops in a vein, was three times higher…
A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Adicet Bio’s CAR T-cell therapy ADI-001 in people with autoimmune diseases, including ANCA-associated vasculitis (AAV), has started recruiting certain participants — and it’s expected to enroll AAV patients by the end of the year — the…
Patterns of lung damage on CT scans may help predict disease outcomes in people with ANCA-associated vasculitis (AAV) and determine which patients should receive more intensive treatment, a study in Germany suggests. Particularly, ground glass opacities (GGO), which are white diffuse regions due to fluid, airway collapse, tissue scarring,…
Get regular updates to your inbox.
